Related Experiment Video

Updated: Apr 10, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.7K

Gender-Specific Differences in Clinical Profile and Biochemical Parameters in Patients with Cushing's Disease: A

Xiaoxia Liu1, Xiaoming Zhu1, Meifang Zeng1

  • 1Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.

International Journal of Endocrinology
|June 12, 2015
PubMed

Insights

Males with Cushing's disease (CD) exhibit more severe clinical presentations and adverse outcomes. This study highlights significant gender differences in CD, emphasizing the need for focused clinical attention on male patients.

Area of Science:

  • Endocrinology
  • Internal Medicine

Background:

  • Cushing's disease (CD) disproportionately affects females.
  • Males with CD often present with more severe clinical manifestations and poorer outcomes.

Purpose of the Study:

  • To investigate gender-based differences in the clinical profile and biochemical parameters of Cushing's disease.
  • To identify specific risk factors and complications associated with gender in CD patients.

Main Methods:

  • Retrospective analysis of 73 Cushing's disease patients diagnosed between 2012-2013.
  • Comparison of clinical presentations and biochemical data between male and female patients.
  • Multiple linear regression analysis to assess correlations between risk factors and clinical outcomes.

Main Results:

  • Males showed significantly higher levels of ACTH, BMI, HbA1c, systolic blood pressure, and hemoglobin compared to females.
  • Increased incidence of fatty liver and altered hepatic function were observed in males.
  • Gender was a significant predictor for hypokalemia, HbA1c, and systolic blood pressure, with males exhibiting more severe indicators.

Conclusions:

  • Male patients with Cushing's disease experience more severe clinical symptoms, biochemical abnormalities, and complications.
  • Healthcare professionals should increase vigilance in the diagnosis and management of Cushing's disease in males.

More Related Videos

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

10.2K
Skeletal Muscle Gender Dimorphism from Proteomics09:29

Skeletal Muscle Gender Dimorphism from Proteomics

Published on: December 14, 2011

13.0K

Related Concept Videos

Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
4.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
401
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
296
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.0K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
345